Emergent role of the fractalkine axis in dissemination of peritoneal metastasis from epithelial ovarian carcinoma
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Emergent role of the fractalkine axis in dissemination of peritoneal metastasis from epithelial ovarian carcinoma
Authors
Keywords
-
Journal
ONCOGENE
Volume 36, Issue 21, Pages 3025-3036
Publisher
Springer Nature
Online
2016-12-13
DOI
10.1038/onc.2016.456
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2016
- (2016) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- CRISPR/Cas9-Mediated Trp53 and Brca2 Knockout to Generate Improved Murine Models of Ovarian High-Grade Serous Carcinoma
- (2016) J. Walton et al. CANCER RESEARCH
- Novel Small-Molecule CX3CR1 Antagonist Impairs Metastatic Seeding and Colonization of Breast Cancer Cells
- (2016) F. Shen et al. MOLECULAR CANCER RESEARCH
- Ovarian cancer
- (2016) Ursula A. Matulonis et al. Nature Reviews Disease Primers
- Primary debulking surgery and neoadjuvant chemotherapy in the treatment of advanced epithelial ovarian carcinoma
- (2015) Shelly M. Seward et al. CANCER AND METASTASIS REVIEWS
- Role of aggressive surgical cytoreduction in advanced ovarian cancer
- (2015) Suk-Joon Chang et al. Journal of Gynecologic Oncology
- The Fractalkine-Receptor Axis Improves Human Colorectal Cancer Prognosis by Limiting Tumor Metastatic Dissemination
- (2015) Marco Erreni et al. JOURNAL OF IMMUNOLOGY
- GPCR structures in drug design, emerging opportunities with new structures
- (2014) Christofer S. Tautermann BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- “Platinum resistant” ovarian cancer: What is it, who to treat and how to measure benefit?
- (2014) Alison Davis et al. GYNECOLOGIC ONCOLOGY
- Pharmacological inhibition of the chemokine receptor CX3CR1 attenuates disease in a chronic-relapsing rat model for multiple sclerosis
- (2014) A. Ridderstad Wollberg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Versican regulates metastasis of epithelial ovarian carcinoma cells and spheroids
- (2014) Mark Desjardins et al. Journal of Ovarian Research
- Reversing Platinum Resistance in High-Grade Serous Ovarian Carcinoma: Targeting BRCA and the Homologous Recombination System
- (2014) W. Ruprecht Wiedemeyer et al. Frontiers in Oncology
- Origin and molecular pathogenesis of ovarian high-grade serous carcinoma
- (2013) R. J. Kurman ANNALS OF ONCOLOGY
- Coming into focus: the nonovarian origins of ovarian cancer
- (2013) L. Dubeau et al. ANNALS OF ONCOLOGY
- Ovarian cancer microenvironment: implications for cancer dissemination and chemoresistance acquisition
- (2013) Benoît Thibault et al. CANCER AND METASTASIS REVIEWS
- Sensitivity and resistance to treatment in the primary management of epithelial ovarian cancer
- (2013) Pierre-Emmanuel Colombo et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Substituted 7-Amino-5-thio-thiazolo[4,5-d]pyrimidines as Potent and Selective Antagonists of the Fractalkine Receptor (CX3CR1)
- (2013) Sofia Karlström et al. JOURNAL OF MEDICINAL CHEMISTRY
- Through the glass darkly: intraepithelial neoplasia, top-down differentiation, and the road to ovarian cancer
- (2013) Christopher P Crum et al. JOURNAL OF PATHOLOGY
- Fractalkine receptor is expressed in mature ovarian teratomas and required for epidermal lineage differentiation
- (2013) Lisa Rooper et al. Journal of Ovarian Research
- First-line Chemotherapy in Epithelial Ovarian Cancer
- (2012) MICHAEL A. BOOKMAN CLINICAL OBSTETRICS AND GYNECOLOGY
- The Lymphotactin Receptor Is Expressed in Epithelial Ovarian Carcinoma and Contributes to Cell Migration and Proliferation
- (2012) M. Kim et al. MOLECULAR CANCER RESEARCH
- An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT)
- (2011) Dennis S. Chi et al. GYNECOLOGIC ONCOLOGY
- CX3CR1 regulates intestinal macrophage homeostasis, bacterial translocation, and colitogenic Th17 responses in mice
- (2011) Oscar Medina-Contreras et al. JOURNAL OF CLINICAL INVESTIGATION
- Fractalkine Receptor CX3CR1 Is Expressed in Epithelial Ovarian Carcinoma Cells and Required for Motility and Adhesion to Peritoneal Mesothelial Cells
- (2011) M. Kim et al. MOLECULAR CANCER RESEARCH
- Identification of the Chemokine CX3CL1 as a New Regulator of Malignant Cell Proliferation in Epithelial Ovarian Cancer
- (2011) Françoise Gaudin et al. PLoS One
- Ovarian Cancer Spheroids Use Myosin-Generated Force to Clear the Mesothelium
- (2011) Marcin P. Iwanicki et al. Cancer Discovery
- Ovarian Cancer Development and Metastasis
- (2010) Ernst Lengyel AMERICAN JOURNAL OF PATHOLOGY
- The Origin of Ovarian Carcinomas
- (2010) Nelly Auersperg INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY
- The chemokine system in cancer biology and therapy
- (2009) Alberto Mantovani et al. CYTOKINE & GROWTH FACTOR REVIEWS
- An engineered CX3CR1 antagonist endowed with anti-inflammatory activity
- (2009) Karim Dorgham et al. JOURNAL OF LEUKOCYTE BIOLOGY
- CX3CR1 Is Expressed by Prostate Epithelial Cells and Androgens Regulate the Levels of CX3CL1/Fractalkine in the Bone Marrow: Potential Role in Prostate Cancer Bone Tropism
- (2008) W. L. Jamieson et al. CANCER RESEARCH
- The Chemokine Receptor CX3CR1 Is Involved in the Neural Tropism and Malignant Behavior of Pancreatic Ductal Adenocarcinoma
- (2008) Federica Marchesi et al. CANCER RESEARCH
- The cell of origin of ovarian epithelial tumours
- (2008) Louis Dubeau LANCET ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started